Tern Plc Konektio £2.5 million equity fundraise

IoT

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that its portfolio company, InVMA Limited, which trades as Konektio has agreed a £2.5 million equity fundraise, to be completed in two tranches. The first tranche of £1.2 million has completed and the second tranche of £1.3 million is due for completion in Q4 2023.

Tern has invested £100,000 in the Konektio First Tranche, with the remainder provided by Konektio’s other institutional shareholders, being Mercia and Foresight.  Prior to the Konektio First Tranche, Tern had a shareholding of 39.9% in Konektio with an unaudited book valuation of £1.0 million.  Post the Konektio First Tranche, Tern’s shareholding in Konektio has reduced to 28% (before any dilution on exercise of any Konektio employee share options) and Tern’s shareholding now has an unaudited book valuation, at the Konektio First Tranche price, of £0.9 million.  

Including its participation in the Konektio First Tranche, Tern has, to date, invested approximately £2.3 million in Konektio.  The pre-new money valuation for the Konektio First Tranche is approximately equivalent to the pre-money valuation for the previous Konektio fundraise announced on 25 April 2023, with Konektio having increased its employee share option pool.

Tern Plc has committed to invest a minimum of £0.28 million in the Konektio Second Tranche, with an option, at its sole discretion, to increase its investment amount up to £0.4 million.  The price of the Konektio Second Tranche will be determined as at 30 September 2023 and will be based on the annualised revenues of Konektio at that time, capped at a pre money valuation of £6.0 million.  Should Tern not fulfil its commitment to invest a minimum of £0.28 million in the Konektio Second Tranche, 75% of Tern’s holding in Konektio will be transferred to a valueless class of Konektio deferred shares.

About Konektio

Konektio provides an Industrial IoT Software as a Service platform to Original Equipment Manufacturers and aftermarket customers, as well as the connected product market. The software enables remote asset monitoring and management to drive productivity improvements. Konektio’s primary product, AssetMinder, is machine agnostic and allows manufacturers to diagnose issues and proactively prescribe services plans, ultimately reducing downtime and improving operational efficiency.  According to the latest filed financial statements for Konektio, for the 12 month period ended 31 December 2021, the business recorded an increase in retained unaudited losses of £0.4 million and at that date had unaudited net assets of approximately £1.8 million.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search